Clearmind Medicines (CMND) surged nearly 65% pre-market, eyeing its biggest gain since 2022. The move followed President Trump's executive order fast-tracking psychedelic approvals and allocating $50 million in funding. Additionally, Clearmind reported positive early-stage trial results for its Alcohol Use Disorder drug CMND-100, which met primary goals with strong safety.